Collectively, this study suggests that MSI2 may ﻿improve the prognosis of CRC patients by reprogramming the tumor immune microenvironment (TIME) through HMGB1-mediated PTMs, which ﻿might be a novel therapeutic option for CRC immunotherapy. This evidence concerns the gene MSI2 and neoplasm.